PPARGC1A and inflammatory bowel disease: In this context, directly modulating mitochondrial metabolism in T cells using approved drugs or novel small-molecule inhibitors like fenofibrate or carnitine-derived molecules, which provide alternative mitochondrial energy sources by enhancing fatty acid oxidation, resvetrarol, a PGC-1α modulator which enhances mitochondrial biogenesis, or the Drp1 inhibitor Mdivi-1, which prevents excessive mitochondrial fission, may account for novel strategies in IBD treatment [33,34,35].